In hemodialysis and in immunocompromised subjects the sensitivity of anti-HCV EIAs is lower, ranging from 50 to 95%, according to the depth of immunosuppression.5-9 False HCV EIAs negative results have also been reported in patients with HCV-associated mixed cryoglobulinemia, probably related to the concentration of anti-HCV antibodies within cryoglobulin complex.10 The third-generation EIAs have shortened the seroconversion time by 2-3 weeks11 and are now the most widely used screening test for HCV.12,13 They are suitable for screening at-risk populations and are recommended as initial test for patients with liver disease.14 The very high sensitivity and specificity prevent the need for confirmatory immunoblot assay in the diagnosis for patients with liver disease,15 while a negative EIA test is sufficient to exclude a chronic infection in immune-competent patients.14 Supplementary or confirmatory assays Supplemental tests have been developed to establish the true positivity of anti-HCV EIA tests results
Cardona, Shweta Urva, Paul J
Instead, it reveals individual predispositions in peptide signaling pathways that may inform personalized treatment conversations
K., Rijntjes, E., Meyer, F., Kohrle, J
